Env-pseudotyped viruses are valuable reagents for studies of HIV-1 neutralizing antibodies. It is often assumed that all pseudovirus particles are capable of only a single round of infection, making them a safe alternative to work with live HIV-1. In this study, we show that some Env-pseudotyped virus preparations give rise to low levels of replication-competent virus. These levels did not compromise results in the TZM-bl neutralization assay; however, their presence highlights a need to adhere to the same level of biosafety when working with Env-pseudotyped viruses that are required for work with replication competent HIV-1.
S
tudies of neutralizing antibodies in HIV-1-infected individuals and in preclinical and clinical trials of candidate vaccines place a heavy reliance on the use of Envpseudotyped viruses. 1, 2 These pseudotyped viruses are produced by cotransfecting 293T or other suitable cell lines with an Env expression vector and an Env-defective backbone vector. One popular backbone vector, pSG3Denv, is a fulllength HIV-1 subtype B genome in plasmid pTZ19U that contains a four nucleotide insertion that inactivates the env gene (NIH AIDS Reagent Program, catalogue #11051; contributed by Drs. John C. Kappes and Xiaoyun Wu). Because most of env is preserved in this backbone, potential exists for recombination with the cotransfected functional env gene to produce replication-competent virus (RCV). The presence of RCV could compromise the neutralization assay by representing an unintended viral target for neutralization. It would also highlight a safety concern for pseudoviruses that are presumed to be replication incompetent and therefore low risk. We tested a large number of assay stocks of HIV-1 Envpseudotyped viruses made with the SG3Denv backbone for the presence of RCV. In addition, we tested a subset of these Env-pseudotyped viruses made with HIV-1 subtype A backbone, Q23Denv, containing a 431 base pair deletion of the V1-C2 region of gp120. 3 We also tested a small subset of Envpseudotyped viruses made with an alternate HIV-1 subtype B backbone, NL4-3.Luc.R -E -. 4 Both backbone vectors are available from the NIH AIDS Reagent Program (Q23Denv catalogue #11548, contributed by Dr. Julie Overbaugh; NL4-3.Luc.R -E -catalogue #3418, contributed by Dr. Nathaniel Landau). All Env-pseudotyped viruses were prepared as described. 5 Phytohemagglutinin-stimulated human peripheral blood mononuclear cells (PHA-PBMCs) were inoculated with undiluted Env pseudovirus preparations in 96-well roundbottom culture plates in the presence of IL-2.
6 PHA-PBMCs were washed after 1 day to remove the virus inoculum and the medium was replaced. Fresh PHA-PBMCs were added on day 7. Cultures were incubated for 12-14 days with regular changing of the medium every 3 days. Culture fluids from days 7, 10, and the final day of incubation were tested for the presence of p24 Gag antigen (PerkinElmer Life Sciences, Inc., Boston, MA). Culture fluids on the final day of incubation were further tested for infectious virus by transferring 50 ll to 96-well plates containing TZM-bl cells in a total volume of 250 ll/well (this transfer was made before collecting culture fluid for p24 assay). Luciferase reporter activity was measured after two days of incubation as described. 5 Samples were considered RCV positive if elevated levels of both p24 Gag antigen and relative luminescence units (RLU) were detected. All assays used the same pool of donor PBMC, which was prescreened and found to be negative for HIV-1.
As seen in Table 1 , 17% (20/117) of Env-pseudotyped virus preparations tested positive for RCV. Four independent preparations of the subtype B pseudovirus, SF162.LS, were positive when made with the SG3DEnv backbone. One of two preparations of this pseudovirus was positive when made with the subtype A backbone, Q23Denv, whereas two preparations made RLU, values >9,000 were considered positive and are bolded; p24 values >3 ng/ml were considered positive and are bolded. Envpseudotyped viruses that tested positive for both RLU and p24 are also bolded.
PBMC, peripheral blood mononuclear cell; RLU, relative luminescence units.
with the NL4-3.Luc.R -E -backbone were both negative. Among six different preparations of subtype B pseudovirus QH0692.42 made with the SG3Denv backbone, three tested positive for RCV. One of three different preparations of the subtype B pseudovirus THRO4156.18 made with SG3Denv backbone was positive. In other cases, multiple preparations of the same pseudoviruses made with the SG3Denv backbone were consistently negative (e.g., AC10.0.29, CAAN5342.A2, REJO4541 .67, SC422661.8, TRJO4551.58, TRO.11, and ZM197M.PB7 Envs). Thus, certain Envs appear to have a greater tendency to generate RCV than others. This tendency may also be related to the backbone vector. Thus, nonsubtype B viruses made with the subtype B backbone SG3Denv were rarely RCV positive (1/41 cases positive, where the only positive was ZM53M.PB12, a subtype C Env). Among seven subtype A pseudoviruses made with the subtype A backbone Q23Denv, one tested positive and this single positive was an Env that was isogenic to the vector (Q23.17). Overall, of the 20 RCV-positive tests, only two occurred when the subtype of the Env and backbone were mismatched (SF162.LS made with Q23Denv; ZM53M.PB12 made with SG3Denv). These results indicate that the potential to generate RCV may be greater when using a backbone that is matched to the subtype of the Env clone. That being said, use of a nonsubtype-matched backbone vector is no guarantee that RCV will be avoided.
To confirm that recombination did in fact occur, we repeated a set of PBMC infection assays with three transfection stocks of Env pseudoviruses that tested positive for RCV and determined the Env sequences in the infected PBMC. These repeat tests were performed with the SG3DEnv backbone pseudotyped with BZ167.12 and 62357.14.D3.4589 Envs and with the Q23Denv backbone pseudotyped with SF162.LS Env. All three transfection stocks of pseudoviruses once again tested positive for p24 Gag antigen after 10 days of PBMC infection.
Bulk gp160 sequencing of PBMC DNA was performed as described previously. 7 Sequence analysis revealed the presence of recombinant gp160 genes in all three cases, where the defective region of the backbone gp160 was replaced with an overlapping region of the pseudotype gp160 (Fig. 1) .
We next tested whether RCV impacted the outcome of neutralization assays performed in TZM-bl cells. Any impact would depend on where the RCV arose (i.e., during transfection or after infection) and how much RCV was present. Any RCV that arose after infection in TZM-bl cells would be of little consequence for an assay that is not incubated long enough to detect multiple rounds of infection. In contrast, if recombination occurred during transfection, the resulting virus would be a mixed population containing the intended Env and a recombinant Env containing elements of the backbone vector. In this latter case, levels of RCV that are sufficient to register in the assay might complicate the results by measuring neutralization of the RCV rather than solely the intended virus.
For our tests, we selected two separate stocks of SF162.LS and one stock of QH0692.42 that scored among the highest RCV values. These transfection stocks of Env-pseudotyped viruses that tested positive for RCV were assayed in parallel with a transfection stock of each Env-pseudotyped virus that tested negative for RCV. All Env-pseudotyped viruses were made with the SG3Denv backbone except for the RCVnegative stock of SF162.LS, which was made with the NL4-3.Luc.R -E -backbone. Assays were performed in TZM-bl cells 5 using 13 HIV-1 plasma samples, soluble CD4, and the monoclonal antibodies IgG1b12, 2G12, 2F5, and 4E10. Equivalent neutralization results were obtained with all reagents regardless of RCV status (<3-fold difference in ID50 neutralization titers between RCV positive and negative pairs of Env-pseudotyped viruses, data not shown). These results indicate that the level of RCV present in these Env-pseudotyped FIG. 1. Genetic recombination in replication-competent virus. Shown are the recombination events that occurred between backbone and pseudotyped env genes detected in peripheral blood mononuclear cell DNA 10 days after infection with three different transfection stocks of Env-pseudotyped viruses. Backbone Env segments are shaded gray. Pseudotyped Env segments are not shaded. Nucleotide residues at the borders of mutations (backbone vectors) and regions of recombination are shown above each Env.
HIV-1 ENV-PSEUDOTYPED VIRUSESviral preparations had no measurable effect on the TZM-bl neutralization assay.
Regardless of the lack of measurable impact of RCV on the results of neutralization assays, the real potential for RCV to be present at low levels in Env-pseudotyped virus preparations should raise awareness for laboratory personnel who may consider Env-pseudotyped viruses to be less of a risk and, therefore, require a lower level of biosafety than work with replication-competent HIV-1. We strongly recommend that all laboratory procedures with HIV-1 Env-pseudotyped viruses be conducted using the same level of biosafety that is required for work with replication competent HIV-1. At the very least, rigorous testing for RCV should be performed on all pseudovirus preparations before initiating work at a lower biosafety level.
